Equihealth FZCO operates across pharmaceutical trade lanes connecting manufacturing economies in India, China, and Europe with consuming markets across South Asia, Southeast Asia, East Asia, and North Africa. Dubai sits at the centre of this network — both geographically and commercially.
The markets below represent Equihealth's current active and target export destinations, structured by region. Sourcing markets are covered separately.
Bangladesh operates one of the most active generic pharmaceutical formulation industries in South Asia. Local manufacturers produce a significant volume of finished dosage forms for domestic consumption and regional export, creating recurring demand for APIs and pharmaceutical raw materials. Equihealth targets this market as a primary buyer destination for bulk APIs and raw materials sourced from India, China, and Europe.
Pakistan's pharmaceutical sector includes an established base of generic drug manufacturers with consistent API and raw material requirements. Cross-border trade finance and payment infrastructure between Pakistan and overseas suppliers benefits from a professionally managed UAE-based intermediary. Equihealth provides a structured commercial route for Pakistani manufacturers to source from Asian and European API producers.
India functions as both a sourcing and receiving market for Equihealth. India is the world's largest exporter of generic pharmaceuticals and a major source of APIs and raw materials in Equihealth's supply network. At the same time, specific product categories and trade flows also position India as a buyer within our trading structure.
Singapore functions as a regulated pharmaceutical hub and a gateway to broader Southeast Asian markets. Buyers in Singapore operate to high documentation and quality standards, consistent with the regulatory environment of the Singapore Health Sciences Authority. Equihealth's compliant documentation practices and structured trading model make it a credible supplier-side partner for Singapore-based pharmaceutical buyers.
Indonesia is the largest economy in Southeast Asia and a significant pharmaceutical market by volume. The country's large population and growing healthcare demand drive consistent import requirements for APIs and finished pharmaceutical goods. Equihealth targets pharmaceutical manufacturers and importers in Indonesia as a key component of its Southeast Asian buyer network.
Vietnam's pharmaceutical manufacturing sector has grown significantly in recent years, with an increasing number of generic drug producers requiring access to international API and raw material sources. Equihealth's trading structure provides Vietnamese manufacturers with a commercially sound and documentation-compliant route to source from India, China, and Europe.
Malaysia hosts an active pharmaceutical manufacturing base with requirements for APIs and pharmaceutical-grade raw materials across a range of therapeutic categories. Equihealth's Dubai-based trading structure aligns with the trade finance and documentation standards that Malaysian pharmaceutical buyers operate to.
Thailand's healthcare sector includes both domestic manufacturers and regional distribution operations that source pharmaceutical products internationally. Equihealth targets both categories within its Thai market coverage.
China is simultaneously Equihealth's largest single sourcing market and a target export market for specific product categories. While the majority of our China relationship is on the supply side — sourcing APIs and raw materials from Chinese manufacturers — specific trade flows into China exist for product categories where Equihealth can add value as an international trading intermediary.
Hong Kong's role as a regional pharmaceutical trading and distribution hub makes it a relevant market for Equihealth's intermediary trading model. Buyers and distributors operating in Hong Kong often source products that require documentation standards consistent with both regional and international regulatory expectations.
Egypt is the largest pharmaceutical market in Africa and one of the most active in the MENA region. Egyptian pharmaceutical manufacturers operate a growing generic drug production base and represent a viable buyer segment for Equihealth's API and raw material trading activity.